Identification

Name
Pregnenolone
Accession Number
DB02789  (EXPT02608)
Type
Small Molecule
Groups
Experimental
Description

A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS. [PubChem]

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Pregnenolone acetate0G0WWV404B1778-02-5CRRKVZVYZQXICQ-RJJCNJEVSA-N
Categories
UNII
73R90F7MQ8
CAS number
Not Available
Weight
Average: 316.4776
Monoisotopic: 316.240230268
Chemical Formula
C21H32O2
InChI Key
ORNBQBCIOKFOEO-QGVNFLHTSA-N
InChI
InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1
IUPAC Name
1-[(1S,2R,5S,10S,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-14-yl]ethan-1-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USulfotransferase family cytosolic 2B member 1Not AvailableHuman
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pregnenolone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pregnenolone.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pregnenolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pregnenolone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pregnenolone.Approved, Withdrawn
AldesleukinPregnenolone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Pregnenolone can be decreased when combined with Algeldrate.Experimental
AlmagateThe bioavailability of Pregnenolone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Pregnenolone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pregnenolone.Experimental
AloglutamolThe bioavailability of Pregnenolone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Pregnenolone.Experimental
AluminiumThe bioavailability of Pregnenolone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Pregnenolone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Pregnenolone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Pregnenolone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Pregnenolone.Approved
AmiodaroneThe serum concentration of Pregnenolone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BPregnenolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pregnenolone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pregnenolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pregnenolone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Pregnenolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Pregnenolone.Approved, Investigational
AprepitantThe serum concentration of Pregnenolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Pregnenolone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Pregnenolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pregnenolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pregnenolone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pregnenolone.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Pregnenolone.Experimental
BendroflumethiazidePregnenolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Pregnenolone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pregnenolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Pregnenolone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Pregnenolone.Experimental
Bismuth SubcitrateThe bioavailability of Pregnenolone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Pregnenolone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Pregnenolone can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pregnenolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pregnenolone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pregnenolone.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Pregnenolone.Experimental
BumetanidePregnenolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Pregnenolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Pregnenolone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Pregnenolone can be decreased when combined with Calcium silicate.Experimental
Capromab pendetidePregnenolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Pregnenolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pregnenolone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pregnenolone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pregnenolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pregnenolone.Approved, Investigational
CeritinibPregnenolone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pregnenolone.Approved, Vet Approved
ChlorothiazidePregnenolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Pregnenolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidonePregnenolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pregnenolone.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Pregnenolone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Pregnenolone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pregnenolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Pregnenolone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Pregnenolone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Pregnenolone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pregnenolone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Pregnenolone.Investigational
CyclopenthiazidePregnenolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Pregnenolone.Investigational
DaidzeinThe serum concentration of Pregnenolone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Pregnenolone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Pregnenolone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pregnenolone.Approved, Vet Approved
DienestrolThe serum concentration of Pregnenolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Pregnenolone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Pregnenolone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pregnenolone.Approved
DihydrotestosteronePregnenolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Pregnenolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pregnenolone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Pregnenolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Pregnenolone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Pregnenolone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Pregnenolone.Approved
EquolThe serum concentration of Pregnenolone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Pregnenolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Pregnenolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Pregnenolone can be increased when it is combined with Estrone.Approved
Etacrynic acidPregnenolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pregnenolone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Pregnenolone.Experimental
Ethinyl EstradiolThe serum concentration of Pregnenolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pregnenolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pregnenolone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pregnenolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pregnenolone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Pregnenolone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Pregnenolone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pregnenolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pregnenolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pregnenolone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Pregnenolone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pregnenolone.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pregnenolone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Pregnenolone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Pregnenolone.Experimental
FluoxymesteronePregnenolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pregnenolone.Approved, Investigational
FosaprepitantThe serum concentration of Pregnenolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Pregnenolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePregnenolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Pregnenolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Pregnenolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Pregnenolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ginkgo biloba.Approved, Nutraceutical
GLPG-0492Pregnenolone may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Pregnenolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Pregnenolone.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Pregnenolone.Experimental
HexestrolThe serum concentration of Pregnenolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Pregnenolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pregnenolone.Approved, Investigational
HydrochlorothiazidePregnenolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePregnenolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Pregnenolone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pregnenolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Pregnenolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Pregnenolone.Approved
IdelalisibThe serum concentration of Pregnenolone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Pregnenolone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Pregnenolone.Approved
IndapamidePregnenolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Pregnenolone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pregnenolone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pregnenolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pregnenolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Pregnenolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pregnenolone is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Pregnenolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pregnenolone.Withdrawn
ItraconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pregnenolone.Experimental
KetoconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pregnenolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pregnenolone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Pregnenolone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pregnenolone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Pregnenolone.Experimental
LopinavirThe serum concentration of Pregnenolone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pregnenolone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pregnenolone.Approved
LumacaftorThe serum concentration of Pregnenolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pregnenolone.Approved, Investigational
MagaldrateThe bioavailability of Pregnenolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Pregnenolone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Pregnenolone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Pregnenolone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pregnenolone.Approved
Magnesium silicateThe bioavailability of Pregnenolone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Pregnenolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pregnenolone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pregnenolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pregnenolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pregnenolone.Approved
MesterolonePregnenolone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Pregnenolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pregnenolone.Withdrawn
MethallenestrilThe serum concentration of Pregnenolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazidePregnenolone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteronePregnenolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Metoclopramide.Approved, Investigational
MetolazonePregnenolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Pregnenolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Minaprine.Approved
MitotaneThe serum concentration of Pregnenolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Pregnenolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pregnenolone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Pregnenolone.Experimental
MoxestrolThe serum concentration of Pregnenolone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pregnenolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pregnenolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pregnenolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pregnenolone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pregnenolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nalidixic Acid.Approved
NandrolonePregnenolone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pregnenolone.Approved, Vet Approved
NefazodoneThe serum concentration of Pregnenolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pregnenolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pregnenolone.Approved
NevirapineThe serum concentration of Pregnenolone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Pregnenolone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pregnenolone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pregnenolone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pregnenolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pregnenolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pregnenolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Pregnenolone.Vet Approved
OxandrolonePregnenolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pregnenolone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Oxolinic acid.Experimental
OxymetholonePregnenolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pregnenolone.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pregnenolone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Pregnenolone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Pregnenolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Pregnenolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Pregnenolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pregnenolone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Pregnenolone.Approved, Investigational
PhenytoinThe serum concentration of Pregnenolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pregnenolone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pipemidic acid.Experimental
PiretanidePregnenolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pregnenolone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pregnenolone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Pregnenolone.Experimental
Polyestradiol phosphateThe serum concentration of Pregnenolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePregnenolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pregnenolone.Experimental
PrimidoneThe serum concentration of Pregnenolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Pregnenolone.Experimental
PromestrieneThe serum concentration of Pregnenolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pregnenolone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Pregnenolone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Pregnenolone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Pregnenolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Pregnenolone can be increased when it is combined with Quinestrol.Approved
QuinethazonePregnenolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Pregnenolone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone.Experimental, Investigational
RifabutinThe serum concentration of Pregnenolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Pregnenolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pregnenolone can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Pregnenolone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pregnenolone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rosoxacin.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pregnenolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pregnenolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pregnenolone.Approved
SaquinavirThe serum concentration of Pregnenolone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Pregnenolone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Pregnenolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pregnenolone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pregnenolone.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Sitafloxacin.Experimental
SparfloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Pregnenolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Pregnenolone.Investigational
St. John's WortThe serum concentration of Pregnenolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololPregnenolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Pregnenolone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pregnenolone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pregnenolone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pregnenolone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Pregnenolone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Pregnenolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Pregnenolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tacrine.Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pregnenolone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Pregnenolone.Withdrawn
TelithromycinThe serum concentration of Pregnenolone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Pregnenolone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pregnenolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Pregnenolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pregnenolone.Approved
TestosteronePregnenolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Pregnenolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pregnenolone.Approved
TiboloneThe serum concentration of Pregnenolone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pregnenolone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pregnenolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pregnenolone.Approved
TorasemidePregnenolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pregnenolone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pregnenolone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Trichlorfon.Vet Approved
TrichlormethiazidePregnenolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Pregnenolone.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pregnenolone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPregnenolone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pregnenolone.Approved
ZeranolThe serum concentration of Pregnenolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pregnenolone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pregnenolone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Alexander James Bridges, "Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone." U.S. Patent US20080171728, issued July 17, 2008.

US20080171728
General References
  1. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011]
External Links
KEGG Compound
C01953
PubChem Compound
8955
PubChem Substance
46506718
ChemSpider
8611
BindingDB
50375319
ChEBI
16581
ChEMBL
CHEMBL253363
Therapeutic Targets Database
DNC001147
HET
PLO
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
1q20 / 4j6b / 4nkw
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentSchizophrenic Disorders1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentBrain Injuries,Traumatic1
2CompletedTreatmentMarijuana Dependence1
2RecruitingBasic SciencePerceived Social Isolation1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders / Autism, Early Infantile1
2RecruitingTreatmentCognitive Decline / Painful musculoskeletal conditions / Tiredness1
2RecruitingTreatmentLower Back Pain1
2WithdrawnTreatmentMajor Depressive Disorder (MDD) / Post-Traumatic Stress Disorder (PTSD)1
2, 3CompletedTreatmentSchizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD)1
4CompletedTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD) / Substance Abuse1
4RecruitingTreatmentAlcohol Use Disorder (AUD) / Bipolar Disorder (BD)1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedTreatmentStress Disorders, Post-Traumatic1
Not AvailableCompletedTreatmentTraumatic Brain Injury (TBI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP4.06ALOGPS
logP3.58ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)18.2ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity93.76 m3·mol-1ChemAxon
Polarizability38.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9671
Caco-2 permeable+0.8568
P-glycoprotein substrateSubstrate0.6106
P-glycoprotein inhibitor IInhibitor0.6721
P-glycoprotein inhibitor IINon-inhibitor0.7531
Renal organic cation transporterNon-inhibitor0.7825
CYP450 2C9 substrateNon-substrate0.8333
CYP450 2D6 substrateNon-substrate0.8417
CYP450 3A4 substrateSubstrate0.7594
CYP450 1A2 substrateNon-inhibitor0.9179
CYP450 2C9 inhibitorNon-inhibitor0.9333
CYP450 2D6 inhibitorNon-inhibitor0.9558
CYP450 2C19 inhibitorNon-inhibitor0.9023
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9076
Ames testNon AMES toxic0.9439
CarcinogenicityNon-carcinogens0.9346
BiodegradationNot ready biodegradable0.9379
Rat acute toxicity1.9852 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8779
hERG inhibition (predictor II)Non-inhibitor0.7239
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)GC-MSsplash10-0fic-5910000000-4b4de0891180a420522a
GC-MS Spectrum - EI-BGC-MSsplash10-05o0-2982000000-90eb349ceb4f7cdf4bf0
Mass Spectrum (Electron Ionization)MSsplash10-052f-6920000000-2b11c86505b10fe4485f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-beta-hydroxysteroids / 3-beta-hydroxy delta-5-steroids / Delta-5-steroids / Secondary alcohols / Ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-hydroxy-delta-5-steroid / 3-hydroxysteroid / 3-beta-hydroxysteroid / 3-beta-hydroxy-delta-5-steroid / Oxosteroid / Hydroxysteroid / Delta-5-steroid / Cyclic alcohol
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3beta-hydroxy steroid, 20-oxo steroid, C21-steroid (CHEBI:16581) / Pregnane and derivatives [Fig], Progestagens (C01953) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030088)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid sulfotransferase activity
Specific Function
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs and xenobiotic compounds. Sulf...
Gene Name
SULT2B1
Uniprot ID
O00204
Uniprot Name
Sulfotransferase family cytosolic 2B member 1
Molecular Weight
41307.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28. [PubMed:16054614]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-dependent organic anion transmembrane transporter activity
Specific Function
Transports sulfoconjugated steroid hormones, as well as taurolithocholic acid-3-sulfate and sulfoconjugated pyrenes in a sodium-dependent manner.
Gene Name
SLC10A6
Uniprot ID
Q3KNW5
Uniprot Name
Solute carrier family 10 member 6
Molecular Weight
41258.24 Da
References
  1. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 05:14